Effects of Inclisiran on Systemic Inflammatory Biomarkers: A Systematic Review

Authors

  • Warham Warham Sendana I Community Health Center, Majene Regency, Indonesia
  • Nurul Fitriani Andi Padri Noling Community Health Center, Luwu Regency, Indonesia
  • Wiking Zeth East Walenrang Community Health Center, Luwu Regency, Indonesia
  • Annisa Istiqamah Ahmad Bambang Community Health Center, Mamasa Regency, Indonesia
  • Asdwiyenti Miftahulresty Aksi Bahteramas Regional General Hospital, Kendari Regency, Indonesia
  • Azhim Asshiddiq Suhardi Andi Ara Padang Lambe Community Health Center, Palopo Regency, Indonesia

DOI:

https://doi.org/10.51601/ijhp.v6i1.515

Abstract

Background: Inclisiran is a novel small interfering RNA (siRNA) therapy that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby introducing an innovative method for the regulation of lipid levels. The implications of this intervention regarding systemic inflammatory biomarkers necessitate comprehensive investigation. Objective: To thoroughly evaluate how inclisiran influences inflammatory markers, especially high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), among a group of people identified with hypercholesterolemia or atherosclerotic cardiovascular disease. Methods: A thorough systematic literature review was performed in accordance with the PRISMA 2020 guidelines. A meticulous search was undertaken across three databases (Scopus, ScienceDirect, PubMed) encompassing the timeframe from January 2017 to December 2025. Two independent reviewers engaged in the processes of filtering, extracting information, and quality evaluation by using the Cochrane RoB 2.0 tool, specifically crafted for randomized controlled trials (RCTs). Results: Out of an initial cohort of 304 records, 11 studies met the predetermined inclusion criteria, encompassing 4 noteworthy phase 2-3 randomized controlled trials (RCTs) (ORION-1, -9, -10, -11). Inclisiran revealed considerable reductions in LDL-C concentrations (varying from 47.9% to 52.6%), while demonstrating neutral effects on hs-CRP levels, which encompassed non-significant increases when compared to placebo (for example, from 3.5% to 8.5%). No investigations have provided data pertaining to IL-6 or TNF-α. All RCTs evaluated demonstrated a significantly low propensity for bias. Conclusions: Current empirical research indicates that inclisiran does not significantly influence systemic hs-CRP levels and lacks comprehensive data regarding other essential inflammatory biomarkers. The enhancements noted in cardiovascular wellness tied to this medication seem to be chiefly dictated by major declines in LDL-C concentrations, instead of variations in overall inflammation. Upcoming research on heart health results must incorporate a wide selection of inflammatory indicators to fully explain the complicated impacts of inclisiran.

Downloads

Download data is not yet available.

References

[1] Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325. doi:10.1038/nature10146

[2] Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656

[3] Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144

[4] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25). doi:10.1161/CIR.0000000000000625

[5] Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646

[6] Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018;138(2):131-140. doi:10.1161/CIRCULATIONAHA.118.034032

[7] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914

[8] Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proceedings of the National Academy of Sciences. 2003;100(3):928-933. doi:10.1073/pnas.0335507100

[9] Fitzgerald K, White S, Borodovsky A, et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. New England Journal of Medicine. 2017;376(1):41-51. doi:10.1056/NEJMoa1609243

[10] Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758

[11] Lamb YN. Inclisiran: First Approval. Drugs. 2021;81(3):389-395. doi:10.1007/s40265-021-01473-6

[12] Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 2020;382(16):1520-1530. doi:10.1056/NEJMoa1913805

[13] Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387

[14] CHMP. Leqvio, INN-Inclisiran. www.ema.europa.eu/contact

[15] Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381-386. doi:10.1016/j.atherosclerosis.2011.11.026

[16] Ding Z, Wang X, Liu S, et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovasc Res. 2018;114(13):1738-1751. doi:10.1093/cvr/cvy128

[17] Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117-122. doi:10.1016/j.atherosclerosis.2016.03.010

[18] Almontashiri NAM, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies. PLoS One. 2014;9(9):e106294. doi:10.1371/journal.pone.0106294

[19] Tucker B, Ong KL, Robledo K, Keech A, Patel S. The association of inflammation, triglycerides and lipoprotein(a) with cardiovascular events in the UK Biobank. Eur Heart J. 2024;45(Supplement_1). doi:10.1093/eurheartj/ehae666.2751

[20] Lamabadusuriya D, Jayawardene P, Cader FA, Wickramarachchi U. High-sensitivity C-reactive protein and its role in coronary atherosclerotic disease: a review of current literature. Postgrad Med J. Published online June 30, 2025. doi:10.1093/postmj/qgaf093

[21] Kaptoge S, Seshasai SRK, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578-589. doi:10.1093/eurheartj/eht367

[22] Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction. Circulation. 2000;101(18):2149-2153. doi:10.1161/01.CIR.101.18.2149

[23] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Published online March 29, 2021:n71. doi:10.1136/bmj.n71

[24] Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. Published online August 28, 2019:l4898. doi:10.1136/bmj.l4898

[25] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD

[26] Santos RD, Rocha VZ. Bringing interleukin-6 complexity to preventive cardiology practice? Eur J Prev Cardiol. 2020;27(2):119-121. doi:10.1177/2047487319876765

[27] Huang Y, Yan L, Rong S, Haller H, Kirch T. TNF-α induces endothelial dysfunction via PKC-ζ-dependent NADPH oxidase activation. Journal of Huazhong University of Science and Technology [Medical Sciences]. 2012;32(5):642-647. doi:10.1007/s11596-012-1011-9

[28] Xue Z, Ye M, Jiang H, et al. The Effect of Different Statin‐Based Lipid‐Lowering Strategies on C‐Reactive Protein Levels in Patients With Stable Coronary Artery Disease. Clin Cardiol. 2024;47(6). doi:10.1002/clc.24301

[29] Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018;138(2):131-140. doi:10.1161/CIRCULATIONAHA.118.034032

[30] Marrs JC, Anderson SL. Inclisiran for the treatment of hypercholesterolaemia. Drugs Context. 2024;13:1-9. doi:10.7573/dic.2023-12-3

[31] Katamine M, Minami Y, Ako J. High-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease: The Pathophysiology, Prognosis, and Emerging Therapies. J Atheroscler Thromb. Published online 2025:RV22044. doi:10.5551/jat.RV22044

[32] Menon T, Chahil V, Patel D, Grancorvitz C, Vijayraghavan K. Inflammation and cardiovascular disease – Part I: Mechanisms and biomarkers. Global Translational Medicine. 2025;4(3):1. doi:10.36922/GTM025100023

[33] Sabeel S, Motaung B, Nguyen KA, et al. Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: A systematic review and meta-analysis. PLoS One. 2025;20(5):e0323749. doi:10.1371/journal.pone.0323749

[34] Khan S, Huda B, Bhurka F, Patnaik R, Banerjee Y. Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int J Mol Sci. 2025;26(17):8429. doi:10.3390/ijms26178429

[35] Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646

[36] Goodman SG, Steg PG, Poulouin Y, et al. Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial. J Am Heart Assoc. 2023;12(18). doi:10.1161/JAHA.122.029216

[37] Landmesser U, McGinniss J, Steg PG, et al. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. Eur J Prev Cardiol. 2022;29(14):1842-1851. doi:10.1093/eurjpc/zwac107

[38] Bays HE. Cholesterol-lowering drugs: Focus on Ezetimibe: Cholesterol-lowering drugs: Focus on ezetimibe. European Atherosclerosis Journal. 2022;1(1):14-24. doi:10.56095/eaj.v1i1.8

[39] Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of Bempedoic Acid on Total Cardiovascular Events. JAMA Cardiol. 2024;9(3):245. doi:10.1001/jamacardio.2023.5155.

Downloads

Published

2026-02-23

How to Cite

Warham, W., Fitriani Andi Padri, N., Zeth, W., Istiqamah Ahmad, A., Miftahulresty Aksi, A., & Asshiddiq Suhardi Andi Ara, A. (2026). Effects of Inclisiran on Systemic Inflammatory Biomarkers: A Systematic Review. International Journal of Health and Pharmaceutical (IJHP), 6(1), 409–421. https://doi.org/10.51601/ijhp.v6i1.515

Issue

Vol. 6 No. 1 (2026): February 2026

Section

Articles

License

Copyright (c) 2026 Warham Warham, Nurul Fitriani Andi Padri, Wiking Zeth, Annisa Istiqamah Ahmad, Asdwiyenti Miftahulresty Aksi, Azhim Asshiddiq Suhardi Andi Ara

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.